The ubiquitin-proteasome system degrades viral oncoproteins and other microbial virulence factors; however, the role of endolysosomal degradation pathways in these processes is unclear. Kaposi's sarcoma-associated herpesvirus (KSHV) is the causative agent of Kaposi's sarcoma, and a constitutively active viral G protein-coupled receptor (vGPCR) contributes to the pathogenesis of KSHV-induced tumors. We report that a recently discovered autophagy-related protein, Beclin 2, interacts with KSHV GPCR, facilitates its endolysosomal degradation, and inhibits vGPCR-driven oncogenic signaling. Furthermore, monoallelic loss of Becn2 in mice accelerates the progression of vGPCR-induced lesions that resemble human Kaposi's sarcoma. Taken together, these findings indicate that Beclin 2 is a host antiviral molecule that protects against the pathogenic effects of KSHV GPCR by facilitating its endolysosomal degradation. More broadly, our data suggest a role for host endolysosomal trafficking pathways in regulating viral pathogenesis and oncogenic signaling. 
Furthermore, injection of a small number of endothelial cells expressing vGPCR increases the tumorigenic potential, in a paracrine fashion, of endothelial cells expressing other KSHV latent genes (vCyclin and vFlip), whereas eradication of the small number of vGPCR-expressing cells in established mix-cell tumors induces tumor regression (15, 18) . Moreover, in a nude mouse model of KS driven by transfection of a KSHV bacterial artificial chromosome into bone marrow endothelial-lineage cells, siRNA interference (RNAi)-mediated suppression of vGPCR expression dramatically reduces angiogenesis and tumor formation (19) . In addition, immunocompetent mice that transgenically express doxycycline (DOX)-inducible KSHV GPCR in endothelial cells (hereafter referred to as ikGPCR + ) manifest lesions that strongly resemble human Kaposi's sarcoma (16, 17) . Importantly, the progression of lesions in ikGPCR + mice is reversible because DOX withdrawal leads to significant regression of vGPCR-induced lesions (17) , suggesting that vGPCR-driven oncogenesis is highly dependent on sustained vGPCR expression and signaling.
Based on these previous observations in animal models regarding KSHV GPCR and oncogenesis, we developed the hypothesis that cell-intrinsic mechanisms that decrease vGPCR protein levels may function as an important host defense mechanism for controlling viral oncogenesis. Recently, we showed that the autophagy protein, Beclin 2 (but not the related autophagy protein Beclin 1) is essential for the endolysosomal degradation of certain cellular GPCRs that are regulated by GASP1 rather
Significance
We show that the autophagy-related protein Beclin 2 functions as a newly described cellular regulator of viral G protein-coupled receptors (GPCRs) and as a suppressor of viral GPCR-driven tumorigenesis. Beclin 2 functions in regulating Kaposi's sarcomaassociated herpesvirus-encoded GPCR levels, proinflammatory signaling, and oncogenic activity in mice by facilitating viral GPCR endolysosomal trafficking. This Beclin 2-dependent endolysosomal trafficking and degradation of an oncogenic viral protein may represent a broader and heretofore unappreciated role of the endolysosomal trafficking machinery in innate immunity (by defending against microbial virulence factors) and in tumor suppression (by degrading oncogenic cell surface receptors).
than by ubiquitination and the endosomal sorting complexes required for the transport pathway (20) . This function of Beclin 2, but not Beclin 1, regulates mouse brain cannabinoid receptor levels and metabolism in vivo (20) . Therefore, we investigated whether Beclin 2 may play a role in the endolysosomal degradation of viral GPCRs and thereby represent an important host defense mechanism against KSHV GPCR-induced oncogenic effects. Our results demonstrate a crucial role for Beclin 2 in KSHV GPCR trafficking, proinflammatory signaling, and in vivo tumorigenicity, and thus represent a previously undescribed role for endolysosomal trafficking in innate immunity and the control of viral GPCR-driven oncogenesis.
Results

Beclin 2 Interacts with KSHV GPCR (vGPCR) and Reduces Its Protein
Levels. We investigated whether Beclin family members (21) interact with vGPCR. In HEK293 cells transfected with HA-tagged vGPCR and Flag-tagged human Beclin 1 or Beclin 2, both human Beclin 1 and human Beclin 2 coimmunoprecipitated with vGPCR (Fig. 1A) . We confirmed that endogenous Beclin 1 and Beclin 2 coimmunoprecipitated with HA-vGPCR (Fig. 1B) . Because Beclin 2, but not Beclin 1, overexpression appeared to result in a decrease in HA-vGPCR steady-state levels (Fig. 1A) , we examined whether there was a dose-dependent effect of Beclin 2 on vGPCR protein levels. Indeed, increasing levels of Beclin 2 expression were associated with significant decreases in levels of steady-state vGPCR expression but not of an irrelevant transfected control protein, GFP; in contrast, overexpression of Beclin 1 had no effect on steady-state levels of vGPCR ( Fig. 2A) . Moreover, siRNA knockdown of Beclin 2, but not the related autophagy protein Beclin 1 or another autophagy protein ATG7, resulted in an increase in steady-state levels of vGPCR (Fig. 2B) , although siRNA knockdown of Beclin 2, Beclin 1, and ATG7 resulted in a comparable defect in starvation-induced autophagic flux [as measured by p62 degradation reversed by the lysosomal inhibitor bafilomycin A1 (Baf A1)] (Fig. S1 ). Moreover, siRNA knockdown of Beclin 2 also increased KHSV GPCR levels in body cavity lymphoma cells with lytic KSHV replication (Fig. 2C) . Taken together, our data show that Beclin 2, but not other autophagy proteins such as Beclin 1 or ATG7, regulates cellular levels of vGPCR.
Next, we investigated whether interaction with GASP1 is required for this function of Beclin 2. Previously, we found that Beclin 2 mutants lacking amino acids 69-88 (Δ69-88) or with an I80S substitution mutation are unable to interact with GASP1 and mediate degradation of certain cellular GPCRs (20) . In contrast, these two Beclin 2 mutants coimmunoprecipitated with vGPCR and decreased vGPCR steady-state levels ( Fig. S2 A and  B) . Moreover, we rescued the increase in steady-state vGPCR levels upon Beclin 2 siRNA knockdown by expressing either wild-type siRNA-resistant Beclin 2 or mutant Δ69-88 or I80S siRNA-resistant Beclin 2 ( Fig. S2 C and D) . Thus, the increase in vGPCR steady-state levels with Beclin 2 knockdown is not a result of off-target siRNA effects and, unlike Beclin 2-dependent regulation of cellular GPCRs, Beclin 2-dependent regulation of vGPCR does not require its GASP1-interacting domain.
Beclin 2 Regulates vGPCR Protein Levels Through a Lysosomal
Degradation Pathway. The Beclin 2-dependent decrease in HAvGPCR expression was partially reversed by treatment with the lysosomal inhibitor, Baf A1 (Fig. 3A) , suggesting that Beclin 2 may promote the degradation of KSHV GPCR through a lysosomal-dependent (but autophagy-independent) pathway. To confirm these findings using an independent approach (Fig. S3A) , we followed the fate of fluorescently labeled surface HA-vGPCR (at 4°C) at serial time points after internalization (incubation at 37°C) in the presence or absence of enforced Beclin 2 expression and in the presence or absence of Baf A1. By 90 min after internalization, the percentage of cells expressing vGPCR was significantly less when cotransfected with Beclin 2 versus empty vector control (Fig. 3 B and C) ; this number dropped to almost 15% in the Beclin 2-transfected cells, but remained at ∼70% in the vector-transfected cells (Fig. 3B ). This decrease in vGPCR + cells upon cotransfection with Beclin 2 was completely blocked by treatment with Baf A1 (Fig. 3C) , confirming that Beclin 2 promotes the endolyososomal degradation of vGPCR. To confirm that endogenous Beclin 2 regulates the fate of internalized vGPCR, we compared the percentage of vGPCR + cells treated with noncoding control or beclin 2 siRNA (Fig. S4B ) at 45 min and 180 min after receptor internalization. At 45 min, no differences were observed and vGPCR was predominantly colocalized with the endosomal marker, early endosome antigen 1 (EEA1) (Fig. S3C) ; in contrast, at 180 min, very few (∼10%) vGPCR ( Fig. 3D ). We conclude that increased Beclin 2 expression facilitates the endolysosomal degradation of vGPCR, whereas Beclin 2 knockdown delays intracellular vGPCR degradation.
Beclin 2 Suppresses vGPCR-Induced Oncogenic Signaling. We next investigated whether Beclin 2-dependent regulation of KSHV GPCR levels affects its signaling functions (16, (22) (23) (24) , including activation of the NF-κB transcription factor and the NF-κB-dependent, proinflammatory cytokine IL-6, which is protumorigenic in KSHV-induced tumors (25) (26) (27) (28) (29) . Using NF-κB and IL-6 promoter luciferase reporter assays, we found that enforced Beclin 2, but not Beclin 1, expression inhibits vGPCR-induced NF-κB and IL-6 activation in a dose-dependent manner (Fig. 4 A  and B ). This suppression of vGPCR-induced NF-κB and IL-6 activation was reversed by the lysosomal inhibitor Baf A1 (Fig. 4  C and D) . In addition, expression of Beclin 2 mutants (Δ69-88 and I80S) that do not interact with GASP1 (20) , suppressed vGPCR-induced NF-κB and IL-6 activation as effectively as wild-type Beclin 2 ( Fig. S4 A and B) . Moreover, Beclin 2 enforced expression did not suppress TNF-α-induced NF-κB activation ( Fig. S4 C and D) , suggesting the regulation of vGPCR signaling by Beclin 2 is not a result of nonspecific global suppression of NF-κB activation. We also found that knockdown of Beclin 2, but not of Beclin 1 or ATG7, enhanced vGPCR-mediated NF-κB activation ( Fig. 4E and Fig. S4E ) and IL-6 activation ( Fig. 4F and Fig. S4F ), and this increase was reversed by cotransfection with either wild-type or GASP1 binding-defective Beclin 2 siRNA-resistant mutants (Fig.   4 G and H and Fig. S4 G and H) . Taken together, these data indicate that Beclin 2 regulates vGPCR-induced NF-κB and IL-6 signaling in a lysosomal-dependent (but autophagy-independent) manner, which involves facilitating the endolysosomal degradation of vGPCR. Moreover, this function of Beclin 2 does not require its interaction with GASP1.
Beclin 2 Suppresses KSHV GPCR-Driven Oncogenesis in Vivo. Given our observation that Beclin 2 regulates vGPCR-induced oncogenic signaling in vitro, we investigated whether Beclin 2 plays a role in regulating vGPCR-induced oncogenesis in vivo. We used a previously established mouse model (referred to herein as ikGPCR + mice) in which DOX-inducible expression of KSHV GPCR causes lesions in mice that strongly resemble human cutaneous KS (16, 17) . We crossed ikGPCR + mice with previously described Becn2 +/− mice that are deficient in autophagy and the degradation of certain cellular GPCRs (20) and with Becn1 +/− mice that are deficient in autophagy (30), but not in the degradation of cellular GPCRs (20) . Compared with ikGPCR + ;Becn2 +/+ littermates, ikGPCR + ;Becn2 +/− littermates had a significantly earlier onset of detectable skin lesions following the initiation of DOX administration in the drinking water (Fig. 5A ). This result was not caused by increased water intake (Fig. S5A) or increased serum DOX levels in the ikGPCR . For A-D, similar results were observed in three independent experiments. *P < 0.05; **P < 0.01; ns, not significant; t test.
exposed skin regions. However, at the same time period after DOX treatment, the lesions in the ikGPCR + ;Becn2 +/− mice were more numerous and larger than those observed in ikGPCR + ;Becn2 +/+ mice at the macroscopic level (see representative photos in Fig. 5B ) and they showed a higher density of lesional cells and more inflammatory cells upon histopathological examination (Fig. 5C and Fig. S6 ). Moreover, staining with an antibody against the endothelial cell marker, CD34, revealed a significant increase in CD34 + spindle-shaped cells (Fig. 5C) 
;Becn2
+/− mice (Fig. 5F ). ikGPCR + ;Becn2 +/− mice also had a marked increase in serum levels of IL-6 at the time of death (Fig. 6A) and at 2 and 4 wk after DOX treatment (Fig. 6B) . The variability of IL-6 production among mice is likely a result of individual variation instead of leaky expression from the DOXresponsive ikGPCR allele, as the serum levels of IL-6 in untreated ikGPCR + ;Becn2 +/+ and ikGPCR + ;Becn2 +/− littermate mice were undetectable. The levels of serum IL-6 elevation in ikGPCR
Becn2
+/− mice inversely correlated with duration of survival (Fig.  S7) , consistent with data from previous animal models and human studies, suggesting that IL-6 is an important pathogenic factor in KS-like disease (25) (26) (27) (28) (29) 32) .
Thus, allelic loss of beclin 2 significantly exacerbates KSHV GPCR-induced protumorigenic signaling and KSHV GPCRinduced neoplastic lesions in vivo. These effects are unlikely to be related to autophagy, because ikGPCR + ;Becn1 +/− mice did not have accelerated onset of lesions, earlier mortality, or increased IL-6 production compared with littermate ikGPCR + ; Becn1 +/+ control mice (Fig. S8) . Rather, taken together with our in vitro findings, they most likely reflect a role for Beclin 2 in promoting the endolysosomal degradation of KSHV GPCR and, thereby, in blocking its protumorigenic signaling effects.
Discussion
Our findings demonstrate a crucial role for the endolysosomal degradation of a virally encoded cell-surface receptor in the suppression of proinflammatory signaling and neoplastic disease driven by a viral oncogenic protein. Overexpression of Beclin 2 (but not the related autophagy protein Beclin 1) results in accelerated degradation of vGPCR and decreased proinflammatory signaling that is blocked by lysosomal inhibition, whereas knockdown of Beclin 2 (but not the related autophagy protein Beclin 1) results in delayed degradation of vGPCR and increased proinflammatory signaling. Moreover, allelic loss of Becn2, but not of Becn1, in mice results in accelerated progression and enhanced severity of vGPCR-driven tumorigenesis, as well as increased IL-6 signaling. Therefore, we propose that this Beclin 2-dependent endolysosomal trafficking and degradation of a KSHV oncogenic protein may represent a broader and heretofore unappreciated role of the endolysosomal trafficking machinery in innate immunity (by functioning as a defense against microbial virulence factors) and in tumor suppression (by degrading oncogenic cell surface receptors).
Considerable advances have been made in defining how oncogenic viral factors (e.g., vGPCR, vFLIP, vCyclin, and vIL-6) contribute to KSHV-induced oncogenesis (33, 34) , and how onocogenic herpesviruses evade or manipulate host defense pathways (including autophagy) (35, 36) . However, it is still largely unclear what mechanisms the host uses to successfully defend For A-H, bars represent mean ± SD of triplicate samples and similar results were observed in three independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001; ns, not significant; one-way ANOVA with Dunnett method. See also Fig. S4 .
against oncogenesis driven by γ-herpesviruses. Although immune status (such as HIV-related or iatrogenic immunosuppression) and ethnicity (such as in classic KS and endemic KS) are important determinants of risk of KSHV-associated malignancies (34, 37) , other unexplained factors likely play a role in determining the incidence and prevalence of KS in at-risk populations. Our findings in mice (i.e., the acceleration of disease in vGPCR transgenic mice with allelic loss of Becn2) lead us to speculate that genetic variations in BECN2 (or genes encoding other proteins that may regulate the trafficking of vGPCR) contribute to individual susceptibility to KSHV-associated malignancies in humans. The mechanism by which Beclin 2 protects against KSHV GPCR-induced oncogenesis likely relates to a role in reducing vGPCR protein levels in endothelial cells harboring the transgene and subsequent reduction of IL-6 protumorigenic signaling. Our in vitro studies demonstrate a lysosomal-dependent role for Beclin 2 in reducing vGPCR levels and vGPCR-induction of IL-6 signaling, and our in vivo studies show enhanced vGPCR expression and increased IL-6 production in mice with allelic loss of Becn2. Moreover, the magnitude of IL-6 elevation in Becn2 +/− mice inversely correlates with survival time. Several lines of evidence suggest that IL-6 is a key pathogenic factor in KSHVassociated malignancies (25) (26) (27) (28) (29) 32) . In humans, an IL-6 promoter polymorphism (G-174C), which leads to increased IL-6 expression (38, 39) , is strongly associated with different types of KS, including those that occur in AIDS patients (epidemic KS) (28) , renal transplant recipients (iatrogenic KS) (40) , and a familiar cluster of classic KS (41) . In mice, genetic deletion of IL-6 ablates KSHV-associated multicentric Castleman's disease (26) . Although our studies do not prove a causal relationship between increased IL-6 production and accelerated tumorigenesis and mortality in Becn2 +/− mice, our observations are consistent with the paradigm that IL-6 is a key regulator of KSHV pathogenesis and provide definitive evidence that Beclin 2 regulates KSHV GPCR-induced IL-6 levels in mice.
In conclusion, our findings indicate that the endolysosomal degradation of viral (and potentially other microbial) virulence factors may serve as an important host antipathogen defense mechanism. Previous studies have shown that the canonical autophagy machinery can function in antibacterial and antiviral host defense by delivering intracellular pathogens or components of intracellular pathogens to the lysosome for degradation (2, 36) . Moreover, Beclin 1 and the autophagy pathway has been proposed to function in controlling viral oncogenesis in at least two contexts: monoallelic deletion of Becn1 accelerates neoplastic lesions in the livers of mice that transgenically express hepatitis B envelope protein autophagy (30) and decreased autophagic degradation of a microRNA (miR-224) is postulated to contribute to hepatitis B virus-associated hepatocellular carcinoma in mice and in humans (42) . Our findings suggest that independently of the autophagy machinery, the delivery of viral oncoproteins to the lysosome for degradation (via an endolysosomal trafficking route) may play a crucial role in innate immunity.
Materials and Methods
See SI Materials and Methods for a detailed description. cavity-based lymphoma (Bcbl-1) cells that carry the tetracycline-inducible viral replication and transcription activator (Rta) allele (Bcbl-1.TREx-Rta) were a gift from Jae U. Jung, Keck School of Medicine, University of Southern California, Los Angeles (43) . Mouse strains used in this study have been previously described, including Becn1 +/− (30), Becn2 +/− (20) , and the transgenic mouse strain that expresses tetracycline-inducible KSHV GPCR (ikGPCR + ), known as iORF74 mice in previous studies (16, 17 Luciferase Reporter Assays. NF-κB and IL-6 promoter activity was measured by performing luciferase reporter assays as described in the SI Materials and Methods.
Microscopy Studies. For antibody-pulse labeling, HeLa cells expressing HA-vGPCR were transfected with nontargeting control siRNAs or siRNA targeting beclin 2, incubated with an anti-HA antibody for 45 min on ice, and then incubated for 45-180 min at 37°C to allow vGPCR-antibody complex internalization. All imaging was performed using a Zeiss AxioImager Z2 microscope, and z-stack images were deconvolved with AutoDeBlur, and analyzed with Imaris v7.4.0 (Bitplane). See SI Materials and Methods for details.
